CO6511251A2 - Compuestos quimicos - Google Patents
Compuestos quimicosInfo
- Publication number
- CO6511251A2 CO6511251A2 CO12046238A CO12046238A CO6511251A2 CO 6511251 A2 CO6511251 A2 CO 6511251A2 CO 12046238 A CO12046238 A CO 12046238A CO 12046238 A CO12046238 A CO 12046238A CO 6511251 A2 CO6511251 A2 CO 6511251A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- chemical compounds
- salts
- administration
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se describen compuestos de la Fórmula III. También se describen sales de los compuestos, una composición farmacéutica que comprende los compuestos o las sales, y métodos para tratar una infección por HCV a través de la administración de los compuestos o sales.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23985509P | 2009-09-04 | 2009-09-04 | |
US29732410P | 2010-01-22 | 2010-01-22 | |
US34876710P | 2010-05-27 | 2010-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6511251A2 true CO6511251A2 (es) | 2012-08-31 |
Family
ID=43649589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12046238A CO6511251A2 (es) | 2009-09-04 | 2012-03-16 | Compuestos quimicos |
Country Status (22)
Country | Link |
---|---|
US (6) | US8344155B2 (es) |
EP (2) | EP3006441A1 (es) |
JP (1) | JP5795316B2 (es) |
KR (1) | KR20120076343A (es) |
CN (1) | CN102480971B (es) |
AR (1) | AR078152A1 (es) |
AU (1) | AU2010289762B2 (es) |
BR (1) | BR112012003578A8 (es) |
CA (1) | CA2771327A1 (es) |
CL (1) | CL2012000573A1 (es) |
CO (1) | CO6511251A2 (es) |
CR (1) | CR20120104A (es) |
DO (1) | DOP2012000045A (es) |
EA (1) | EA201290089A1 (es) |
IL (1) | IL217800A0 (es) |
MA (1) | MA33642B1 (es) |
MX (1) | MX2012002759A (es) |
NZ (1) | NZ597982A (es) |
PE (1) | PE20120993A1 (es) |
SG (1) | SG178952A1 (es) |
TW (1) | TW201121974A (es) |
WO (1) | WO2011028596A1 (es) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012513409A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
MX2011006333A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
SG175144A1 (en) | 2009-04-15 | 2011-11-28 | Abbott Lab | Anti-viral compounds |
DK2430014T3 (en) | 2009-05-13 | 2015-11-30 | Gilead Pharmasset Llc | Anti-viral compounds |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
CN102333772B (zh) | 2009-06-11 | 2013-12-11 | 雅培制药有限公司 | 抗病毒化合物 |
US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
IN2012DN00999A (es) | 2009-07-16 | 2015-04-10 | Vertex Pharma | |
US8344155B2 (en) * | 2009-09-04 | 2013-01-01 | Glaxosmith Kline Llc | Chemical compounds |
US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
EP2475256A4 (en) | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
BR112012018529A2 (pt) | 2010-01-25 | 2016-08-09 | Enanta Pharm Inc | inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna |
US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
MX2012010252A (es) | 2010-03-04 | 2013-02-01 | Enanta Pharm Inc | Agentes farmaceuticos en combinacion como inhibidores de la replicacion del virus de hepatitis c (hcv). |
JP2013522375A (ja) | 2010-03-24 | 2013-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染を処置または予防するためのアナログ |
US9127021B2 (en) | 2010-04-09 | 2015-09-08 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
EP2575819A4 (en) * | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
US8697704B2 (en) | 2010-08-12 | 2014-04-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
KR101835474B1 (ko) * | 2010-11-17 | 2018-03-08 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
JP5669984B2 (ja) | 2011-05-18 | 2015-02-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | 5−アザスピロ[2.4]ヘプタン−6−カルボン酸およびその誘導体の製造方法 |
WO2013025975A1 (en) * | 2011-08-17 | 2013-02-21 | Glaxosmithkline Llc | Combination treatments for hepatitis c |
EA201490254A1 (ru) * | 2011-08-24 | 2014-07-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Комбинированное лечение гепатита с |
SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
KR20140091036A (ko) | 2011-11-03 | 2014-07-18 | 세라밴스 인코포레이티드 | 단편 [2-[4-(바이페닐-4-일)-1h-이미다조-2-일]피롤리딘-1-카르보닐메틸]아민을 포함하는 간상 c형 간염 바이러스 억제제 |
SI2907816T1 (sl) | 2011-11-16 | 2018-10-30 | Gilead Pharmasset Llc | Kondenzirani imidazolilimidazoli kot protivirusni sestavki |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9326973B2 (en) * | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2624846T3 (es) | 2012-04-25 | 2017-07-17 | Theravance Biopharma R&D Ip, Llc | Compuestos de piperazina-piperidina como inhibidores del virus de la hepatitis C |
US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
CN104230946B (zh) * | 2013-06-06 | 2017-03-08 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
WO2015026454A1 (en) * | 2013-07-17 | 2015-02-26 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis c virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
FR3022262B1 (fr) * | 2014-06-12 | 2016-06-03 | Michelin & Cie | Cable gomme in situ comprenant une composition de gommage comprenant un inhibiteur de corrosion |
CN105646285B (zh) * | 2014-12-02 | 2017-11-24 | 上海医药工业研究院 | 一种维兰特罗中间体及其制备方法和应用 |
US10206706B2 (en) | 2015-05-29 | 2019-02-19 | Medtronic Xomed, Inc. | Inner tubular member for angled rotary surgical instrument |
WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN105777719A (zh) * | 2016-03-29 | 2016-07-20 | 安徽联创生物医药股份有限公司 | 一种达卡他韦的合成方法 |
JP7161849B2 (ja) * | 2018-01-24 | 2022-10-27 | 株式会社クラレ | 第一級アミンの製造方法 |
CN109456375B (zh) * | 2018-12-11 | 2019-10-22 | 枣庄学院 | 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法 |
JP2024505261A (ja) | 2021-01-29 | 2024-02-05 | セディラ・セラピューティクス・インコーポレイテッド | Cdk2阻害剤およびその使用方法 |
EP4341266A1 (en) | 2021-05-21 | 2024-03-27 | Gilead Sciences, Inc. | Pentacyclic derivatives as zika virus inhibitors |
MX2023015436A (es) | 2021-06-26 | 2024-02-21 | Cedilla Therapeutics Inc | Inhibidores de cdk2 y metodos de uso de los mismos. |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US889145A (en) | 1907-03-16 | 1908-05-26 | Jewel Electric Sign Company | Electric sign. |
US1879057A (en) | 1930-04-05 | 1932-09-27 | Freeman M Bray | Automobile direction signal |
US3931207A (en) | 1973-12-14 | 1976-01-06 | Smithkline Corporation | Tetramic acid analogs of pulvinic acid |
JPS5686723U (es) | 1979-12-07 | 1981-07-11 | ||
US4288672A (en) | 1979-12-26 | 1981-09-08 | Texas Instruments Incorporated | Illuminated keyboard apparatus |
US4493958A (en) | 1983-09-28 | 1985-01-15 | Stewart-Warner Corporation | Illuminated membrane switch |
JPS60252388A (ja) | 1984-05-29 | 1985-12-13 | 株式会社東芝 | 表示装置 |
US4811175A (en) | 1986-07-09 | 1989-03-07 | Desmet Gregory L | Illuminated switch |
FI88345C (fi) | 1991-01-29 | 1993-04-26 | Nokia Mobile Phones Ltd | Belyst tastatur |
US5128842A (en) | 1991-06-03 | 1992-07-07 | Sunarrow Co., Inc. | Uniform illumination plate |
US5432684A (en) | 1994-01-11 | 1995-07-11 | Delco Electronics Corp. | Process for manufacturing painted backlit displays having uniform backlighting intensity |
ATE272062T1 (de) | 1996-08-28 | 2004-08-15 | Procter & Gamble | Spirocyclisch metalloprotease inhibitoren |
US5911317A (en) | 1997-08-26 | 1999-06-15 | Silitek Corporation | Light permeable metal plated rubber key |
US6652128B2 (en) | 2001-01-31 | 2003-11-25 | Textron Automotive Company, Inc. | Backlighting method for an automotive trim panel |
GB0130763D0 (en) | 2001-12-21 | 2002-02-06 | Norgine Res Ltd | Treatment methods |
US6731913B2 (en) | 2002-01-30 | 2004-05-04 | Nokia Corporation | Elastomeric enclosure |
KR20060054410A (ko) | 2003-08-01 | 2006-05-22 | 제네랩스 테크놀로지스, 인코포레이티드 | 플라비비리다에에 대한 2고리 이미다졸 유도체 |
MXPA06006609A (es) | 2003-12-11 | 2006-08-31 | Abbott Lab | Compuestos inhibidores de proteasa de vih. |
WO2005088945A1 (en) | 2004-03-17 | 2005-09-22 | Sensetech Co., Ltd | Metal keypad assembly for mobile phone and manufacturing method of keypad |
EP1844051A1 (en) | 2005-01-19 | 2007-10-17 | Biolipox AB | Thienopyrroles useful in the treatment of inflammation |
US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
US7683279B2 (en) | 2006-02-28 | 2010-03-23 | Hyun Soo Kim | Light emitting keypad comprising light guide film and light guide |
KR100754587B1 (ko) | 2006-03-03 | 2007-09-05 | 삼성전자주식회사 | 전자기기의 키패드 어셈블리 |
US7600880B2 (en) | 2006-06-12 | 2009-10-13 | Motorola, Inc. | Device with modal lighting control and method thereof |
US7745636B2 (en) * | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100158862A1 (en) * | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW200827368A (en) * | 2006-11-21 | 2008-07-01 | Genelabs Tech Inc | Amido anti-viral compounds |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
CA2715400A1 (en) | 2008-02-12 | 2009-08-20 | Bristol-Myers Squibb Company | Heterocyclic derivatives as hepatitis c virus inhibitors |
DK2250163T3 (da) | 2008-02-12 | 2012-07-16 | Bristol Myers Squibb Co | Hepatitis C-virusinhibitorer |
US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2242752B1 (en) * | 2008-02-13 | 2012-08-08 | Bristol-Myers Squibb Company | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102307589A (zh) | 2008-08-28 | 2012-01-04 | 沃泰克斯药物股份有限公司 | Hcv的基因型分析 |
WO2010040077A1 (en) | 2008-10-03 | 2010-04-08 | Osmetech Technology Inc. | Cyp2c9*8 alleles correlate with decreased warfarin metabolism and increased warfarin sensitivity |
WO2010042834A1 (en) | 2008-10-09 | 2010-04-15 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
US8729077B2 (en) | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
BRPI0922364A2 (pt) | 2008-12-03 | 2017-08-29 | Presidio Pharmaceuticals Inc | Composto, composição farmacêutica e uso de um composto |
PT2373172E (pt) | 2008-12-03 | 2013-10-21 | Presidio Pharmaceuticals Inc | Inibidores de ns5a de hcv |
WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
WO2010096462A1 (en) | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
SG10201400235PA (en) | 2009-02-27 | 2014-07-30 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
EP2408449A4 (en) | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
WO2010111673A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
US9150554B2 (en) | 2009-03-27 | 2015-10-06 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
ES2573088T3 (es) | 2009-03-27 | 2016-06-06 | Merck Sharp & Dohme Corp. | Inhibidores de la replicación del virus de la hepatitis C |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI476190B (zh) * | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
SG175144A1 (en) | 2009-04-15 | 2011-11-28 | Abbott Lab | Anti-viral compounds |
EP2421855A1 (en) | 2009-04-24 | 2012-02-29 | Tibotec Pharmaceuticals | Diaryl ethers |
EP2430015B1 (en) | 2009-05-12 | 2015-06-17 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds useful for the treatment of viral diseases |
DK2430014T3 (en) | 2009-05-13 | 2015-11-30 | Gilead Pharmasset Llc | Anti-viral compounds |
WO2010138790A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
CN102333772B (zh) | 2009-06-11 | 2013-12-11 | 雅培制药有限公司 | 抗病毒化合物 |
WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US8221737B2 (en) * | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
IN2012DN00999A (es) | 2009-07-16 | 2015-04-10 | Vertex Pharma | |
EP2467144A1 (en) | 2009-07-24 | 2012-06-27 | ViroLogik GmbH | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
US8344155B2 (en) | 2009-09-04 | 2013-01-01 | Glaxosmith Kline Llc | Chemical compounds |
EP2475256A4 (en) | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US20110137633A1 (en) | 2009-12-03 | 2011-06-09 | Abbott Laboratories | Anti-viral compounds and methods of identifying the same |
US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
MX2012006877A (es) | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
JP2013522375A (ja) | 2010-03-24 | 2013-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染を処置または予防するためのアナログ |
EP2550262A1 (en) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
EA201490254A1 (ru) * | 2011-08-24 | 2014-07-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Комбинированное лечение гепатита с |
-
2010
- 2010-08-26 US US12/936,545 patent/US8344155B2/en not_active Expired - Fee Related
- 2010-08-26 CA CA2771327A patent/CA2771327A1/en not_active Abandoned
- 2010-08-26 EP EP15195410.4A patent/EP3006441A1/en not_active Withdrawn
- 2010-08-26 EA EA201290089A patent/EA201290089A1/ru unknown
- 2010-08-26 SG SG2012014791A patent/SG178952A1/en unknown
- 2010-08-26 NZ NZ597982A patent/NZ597982A/xx not_active IP Right Cessation
- 2010-08-26 KR KR1020127005583A patent/KR20120076343A/ko not_active Application Discontinuation
- 2010-08-26 MX MX2012002759A patent/MX2012002759A/es active IP Right Grant
- 2010-08-26 PE PE2012000291A patent/PE20120993A1/es not_active Application Discontinuation
- 2010-08-26 WO PCT/US2010/046782 patent/WO2011028596A1/en active Application Filing
- 2010-08-26 BR BR112012003578A patent/BR112012003578A8/pt not_active IP Right Cessation
- 2010-08-26 AU AU2010289762A patent/AU2010289762B2/en not_active Expired - Fee Related
- 2010-08-26 CN CN201080039705.4A patent/CN102480971B/zh not_active Expired - Fee Related
- 2010-08-26 JP JP2012527916A patent/JP5795316B2/ja not_active Expired - Fee Related
- 2010-08-26 EP EP10814293A patent/EP2473056A4/en not_active Withdrawn
- 2010-09-02 TW TW099129883A patent/TW201121974A/zh unknown
- 2010-09-02 AR ARP100103221A patent/AR078152A1/es unknown
-
2012
- 2012-01-29 IL IL217800A patent/IL217800A0/en unknown
- 2012-02-21 DO DO2012000045A patent/DOP2012000045A/es unknown
- 2012-02-28 CR CR20120104A patent/CR20120104A/es unknown
- 2012-03-02 CL CL2012000573A patent/CL2012000573A1/es unknown
- 2012-03-16 CO CO12046238A patent/CO6511251A2/es active IP Right Grant
- 2012-04-02 MA MA34737A patent/MA33642B1/fr unknown
- 2012-11-15 US US13/677,358 patent/US8492554B2/en not_active Expired - Fee Related
-
2013
- 2013-06-12 US US13/915,674 patent/US8853416B2/en not_active Expired - Fee Related
-
2014
- 2014-08-28 US US14/472,293 patent/US9150587B2/en not_active Expired - Fee Related
-
2015
- 2015-09-09 US US14/849,190 patent/US20150374668A1/en not_active Abandoned
-
2016
- 2016-02-10 US US15/040,222 patent/US9814699B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6511251A2 (es) | Compuestos quimicos | |
DOP2010000267A (es) | Compuesto heterociclico | |
CY1117615T1 (el) | Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης | |
UY30759A1 (es) | Compuestos quimicos | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
CR11641A (es) | Derivados heterociclicos de urea y metodos de uso de los mismos-211 | |
ECSP10010413A (es) | Inhibidores macrociclicos de serina proteasa | |
EA201170772A1 (ru) | Органические соединения | |
UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
CU20110235A7 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
UY33775A (es) | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos | |
ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
CL2012001959A1 (es) | Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae. | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
CL2009001346A1 (es) | Compuestos derivados heterociclicos, inhibidores de la adn girasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion bacteriana. | |
UY32424A (es) | Comprimidos conteniendo elivitegravir para tratamiento de infecciones virales | |
CR20110680A (es) | Sulfonamidas heterociclicas, usos y composiciones farmacéuticas de las mismas | |
HN2009000566A (es) | Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen. | |
UY31141A1 (es) | Compuestos de piperidina y sus usos | |
UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
UY31864A (es) | Derivados de urea hetericíclica y métodos de uso de los mismos-332 | |
DOP2010000374A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
UY32856A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |